Ann: Change in substantial holding, page-15

One option might be to wait and see if semaglutides cause side-effects (since, if my understanding is correct, the primary reason that the Phase 3 trials of Invex’s main asset, Presendin, were stopped was due to semaglutides being used for weight loss across a large proportion of the potential user base for Presendin which consequently reduced the severity/frequency of conditions involving raised intracranial pressure).

For example, here is an article from the American Academy of Opthalmology, regarding potential (as yet unconfirmed) links between semaglutide usage and increased risk for the blinding eye disease non-arteritic ischemic optic neuropathy (NAION):
https://www.aao.org/eye-health/news/can-ozempic-affect-eye-health-here-s-what-ophthalm